Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tool could revolutionize skin cancer detection in family clinics

NCT ID NCT06932172

Diagnosis Sponsor: Linkoeping University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an AI system called Dermalyser that helps primary care doctors decide if a skin spot might be cancer. About 3,000 adults in five countries will take part. Doctors in some clinics will use the AI tool, while others will follow standard care. The goal is to see if AI can catch more skin cancers early and reduce unnecessary biopsies or specialist visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients attending a primary care facility in order to have one or more skin lesions checked for skin cancer, or patients presenting with one or more skin lesions raising suspicion of skin cancer when noticed by the primary care physician. * Willingness and ability to provide informed consent. Exclusion Criteria: * Individuals with skin type V and VI according to the Fitzpatrick's scale (darker brown or black coloured skin)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skin cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

skin cancer skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Skin cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ekholmen Primary Healthcare Centre

    RECRUITING

    Linköping, 589 29, Sweden

  • Finspång Primary Healthcare Centre

    RECRUITING

    Finspång, Docent, 61230, Sweden

  • Kärna Primary Care Centre

    RECRUITING

    Linköping, Docent, 58662, Sweden

  • Mjölby Primary Care Centre

    RECRUITING

    Mjölby, Docent, 59530, Sweden

  • Skärvet Primary Healthcare Centre

    RECRUITING

    Vaxjo, Docent, 35234, Sweden

  • Valla Primary Healthcare Centre

    RECRUITING

    Linköping, Docent, 58213, Sweden

  • Vikbolandet Primary Care Centre

    RECRUITING

    Norrköping, Docent, 61024, Sweden

  • Åby Primary Healthcare Centre

    RECRUITING

    Norrköping, Docent, 61330, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.